News Industry News HeartWare Completes Enrollment In ENDURANCE2 Supplemental Destination Therapy Trial August 10, 2015
News Industry News Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy June 16, 2015